Literature DB >> 11156450

Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence.

G A Santoro1, B Z Eitan, A Pryde, D C Bartolo.   

Abstract

INTRODUCTION: Amitriptyline, a tricyclic antidepressant agent with anticholinergic and serotoninergic properties has been used empirically in the treatment of idiopathic fecal incontinence with good results.
METHODS: An open study was conducted to test the response to amitriptyline 20 mg daily for four weeks by 18 patients (2 males) of median age 66 years with idiopathic fecal incontinence Incontinence scores, number of bowel movements, computerized ambulatory anorectal pressures, and pudendal nerve terminal motor latencies were evaluated before and after four weeks of therapy. Twenty-four control subjects (10 males) of median age 61 years were also assessed
RESULTS: Amitriptyline improved incontinence scores (median pretreatment score = 16 vs. median posttreatment score = 3; P < 0.001) and reduced the number of bowel movements per day (P < 0.001). Amitriptyline also decreased the frequency (median pretreatment frequency = 4.5 per hour vs. median immediate posttreatment frequency = 1.2 per hour (P < 0.05); control median frequency = 0.3 per hour) and the amplitude of rectal motor complexes (median pretreatment rectal pressure = 94 cm H2O vs. median immediate posttreatment rectal pressure = 58 cm H2O (P < 0.05); control median rectal pressure = 36 cm H2O) and improved anal pressures during these events (P < 0.001).
CONCLUSIONS: Amitriptyline improved symptoms in 89 percent of patients with fecal incontinence. The data support that the major change with amitriptyline is a decrease in the amplitude and frequency of rectal motor complexes. The second conclusion is that drug increases colonic transit time and leads to the formation of a firmer stool that is passed less frequently. These in combination may be the source of the improvement in continence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156450     DOI: 10.1007/BF02236848

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  32 in total

1.  Management of fecal incontinence.

Authors:  Adil E Bharucha
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-11

Review 2.  Investigation and treatment of faecal incontinence.

Authors:  S Maslekar; A Gardiner; C Maklin; G S Duthie
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

Review 3.  Treatment strategies in obstructed defecation and fecal incontinence.

Authors:  Marat Khaikin; Steven-D Wexner
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

4.  Consensus conference on faecal incontinence.

Authors:  C Baeten; D C C Bartolo; P A Lehur; K Matzel; M Pescatori; B Roche; N S Williams
Journal:  Tech Coloproctol       Date:  2007-08-03       Impact factor: 3.781

5.  Effect of nifedipine on anorectal sensorimotor functions in health and fecal incontinence.

Authors:  Adil E Bharucha; Jessica Edge; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-04-14       Impact factor: 4.052

6.  Towards safer treatments for benign anorectal disease: the pharmacological manipulation of the internal anal sphincter.

Authors:  Oliver M Jones
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

Review 7.  Investigating and treating fecal incontinence: when and how.

Authors:  Adriana Lazarescu; Geoffrey K Turnbull; Stephen Vanner
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

8.  Fecal incontinence.

Authors:  Tracy Hull
Journal:  Clin Colon Rectal Surg       Date:  2007-05

Review 9.  Medical management of fecal incontinence in challenging populations: a review.

Authors:  David Lee; Gaurav Arora
Journal:  Clin Colon Rectal Surg       Date:  2014-09

Review 10.  Anal incontinence-sphincter ani repair: indications, techniques, outcome.

Authors:  Susan Galandiuk; Leslie A Roth; Quincy J Greene
Journal:  Langenbecks Arch Surg       Date:  2008-05-06       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.